In a 286-patient Phase 2 trial, elraglusib combined with gemcitabine/nab-paclitaxel achieved a statistically significant ...

Johnson & Johnson’s Oncology Care Index reveals 73% of oncologists see a gap between new cancer treatments and clinical ...

Phase III POTOMAC trial showed that adding Durvalumab (Imfinzi) to BCG induction and maintenance therapy significantly ...

The Phase III DESTINY-Breast11 trial showed Enhertu followed by THP significantly improved pathologic complete response (pCR) ...

For the first time, the FDA completed a generative AI-assisted scientific review pilot, cutting review tasks from days to ...